Late last night the FDA announced they had approved the new #schizophrenia drug Cobenfy (formerly KarXT). Terran CEO Sam Clark Sam Clark, MD PhD spoke with Chelsie Derman at HCPLive, and shared his thoughts on this big win for patients and the implications for new innovation.

Today at 10:00am ET, Terran’s founder and CEO, Sam Clark, MD PhD Sam Clark, MD PhD will be presenting on our unique prodrug approach to create novel therapeutics like TerXT for the treatment of #schizophrenia. Register for the webinar below:

Terran CEO Sam Clark Sam Clark, MD PhD shared his thoughts on what the FDA’s recent approval of KarXT (Cobenfy) means for #schizophrenia patients and for new innovation in this article by Melissa Rudy at Fox News alongside commentary by Bristol Myers Squibb CEO: foxnews.com/health/new-sch…

Terran’s CEO Sam Clark Sam Clark, MD PhD connected with Kelly Bilodeau at @pharmavoice for her article alongside KARUNA THERAPEUTICS founder Andrew Miller to discuss the recent FDA approval of KarXT (Cobenfy) for #schizophrenia and future innovations like TerXT. pharmavoice.com/news/bms-karxt…

As a global leader in psychedelic manufacturing and supply, Terran is excited to provide psilocybin, LSD, and DMT, to Gitte Moos Knudsen’s lab at Neurobiology Research Unit, Rigshospitalet to support their groundbreaking research in psychiatry and neurology. These are some of the many psychedelic

Terran's CEO Sam Clark Sam Clark, MD PhD moderated an HCPLive panel alongside key opinion leaders Dr. Andrew Cutler and Dr. Rishi Kakar (lead investigator on the KarXT trials), to discuss the FDA approval of KarXT (Cobenfy) for #schizophrenia, and what this means for patients and

The Terran team is thrilled to have been selected as a Fierce Life Science Innovation Award finalist for our FDA-approved NM-101 software technology to aid in the evaluation of #ParkinsonsDisease and other neuropsychiatric conditions. We are honored to be recognized alongside the

We are honored to receive BioTech Breakthrough’s Analytics Innovation of the Year award for NM-101, our FDA-cleared software platform to analyze neuromelanin MRI scans. biotechbreakthroughawards.com/2024-winners/ With this new technology we aim to aid in the evaluation of complex neuropsychiatric

Terran CEO Sam Clark Sam Clark, MD PhD was recently featured on The BioHub podcast to discuss recent advances in #schizophrenia, including TerXT, our combination of novel prodrugs of xanomeline and trospium (the same active ingredients in FDA-approved Cobenfy) youtube.com/watch?v=OJQ2dg…

We’re proud to announce that we’ve been granted a U.S. patent for the world’s first new polymorphs of #methylone hydrochloride (US-12234216-B2). Methylone is a rapid acting empathogen with a differentiated profile from MDMA and Terran is currently developing methylone as a

Thank you to Psychedelic Alpha for featuring Terran’s recently-granted composition-of-matter patent on #methylone in their recent review of the landscape. psychedelicalpha.com/news/february-… Terran’s patent covers the salts and polymorphs of racemic methylone HCl (US12,234,216B2), and these